Phase I Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2018
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan (Primary) ; Utomilumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 27 Dec 2017 Planned End Date changed from 1 Feb 2022 to 1 Dec 2021.
- 27 Dec 2017 Planned primary completion date changed from 1 Feb 2022 to 1 Dec 2021.